SHANGHAI, March 09, 2026 — AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially commenced operations. This milestone completes a Shanghai-based “Golden Triangle” footprint comprising the Zhangjiang Center of Biological Technology and Innovation, Jinshan Manufacturing Site, and Fengxian Manufacturing Site. The three locations integrate end-to-end CDMO capabilities from early R&D and process development through clinical pilot-scale production, to commercial manufacturing, advancing client programs from IND to BLA through efficient cross-site coordination.AsymBio’s “Dual Sites + One Center” model provides connected functions and complementary strengths across the biologics lifecycle:• Zhangjiang Center of Biological Technology and Innovation (CBTI): A technology-driven central engine for innovation, focusing on early R&D and process development for antibodies, proteins, novel drug conjugates (NDCs), and other advanced therapies, with forward-looking technology deployment. The Center builds and optimizes technology platforms for cell line development, upstream/downstream process development and optimization, conjugation toolbox development, and analytical method development. It supports concept-to-process translation and enables defined technology transfer pathways for subsequent pilot and commercial manufacturing.• Jinshan Manufacturing Site: A one-stop manufacturing site providing manufacturing services from clinical supply and pilot-scale to commercial production, covering drug substance (DS) and drug product (DP) capabilities for antibodies, protein therapeutics, ADCs, and NDCs. The site supports programs across clinical stages, spanning from R&D to antibody DS/DP and conjugate DS/DP.• Fengxian Manufacturing Site: A newly commissioned intelligent, large-scale, and internationally compliant manufacturing site focused on late-stage development and large-scale commercial supply for antibodies, protein therapeutics, ADCs, and NDCs. It introduces advanced smart manufacturing systems to enable compliant operations and meet global demand for large-scale supply of high-quality biologics.Dual-site GMP manufacturing to flexibly support capacity needs from early pilot to large-scale commercial supply The network is equipped with:• Single-use bioreactors for antibody drug substance: 200 L / 500 L / 2,000 L• Conjugation reactors for conjugate drug substance: 50 L / 100 L / 200 L / 500 L• ORABS fully automated filling line• Multi-specification lyophilization and isolator filling systems: 5 m² / 10 m² / 15 m² / 20 m² lyophilizers, supporting 2R–20R formatsThese capabilities support diverse dosage forms and specifications and strengthen integrated delivery in biologics, enabling customized manufacturing services.Integrating Asymchem’s Payload–Linker Facility to Provide End-to-End, One-Stop Services for Drug ConjugatesAsymBio integrates Asymchem Group resources by linking Shanghai’s conjugation manufacturing with the Group’s Tianjin payload–linker R&D and manufacturing capabilities. The Tianjin site focuses on payload–linker process development and manufacturing while connecting seamlessly with Shanghai's antibody DS, conjugate DS, and DP manufacturing and fill-finish. This end-to-end model enables cross-regional coordination, ensures supply chain stability, and improves both execution efficiency and cross-stage collaboration.With the Fengxian site now in operation, AsymBio’s Shanghai footprint covers the full value chain from early-stage development through commercialization. Through the “Dual Sites + One Center” model and integrated payload–linker capabilities, the company provides global clients with efficient, reliable, and customized development and manufacturing solutions, supporting pipelines from the laboratory to clinical development and commercialization.About AsymBioAsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).For more information: visit www.asymbio.com or follow us on LinkedIn.Business inquiries: MKT@asymchem.com.cn

SHANGHAI, February 10, 2026 — AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows for client programs from early development to commercial manufacturing.AsymBio is a technology-driven biopharmaceutical CDMO focused on accelerating innovation and providing integrated development and manufacturing services for clients. Key platforms include:1. AmigoCHO™ Cell Line Development Platform — Supports the development of high-titer, high-quality, and stable clones, including cell pool establishment, expansion, clone selection, and stability analysis.Upstream Process Development Platform — Covers process optimization, process scale-up, and process characterization, supporting workflows from preclinical material preparation and IND/BLA-enabling process development to technology transfer and scale-up. Project timelines can be shortened to as little as 9 weeks.2. Downstream Process Development Platform — Designed to shorten process development timelines while supporting higher product purity, reduced impurities, and improved yield, including chromatography process development, filtration process development, tech transfer and scale-up, and process characterization.3. Conjugation Toolbox — A modular and flexible toolbox that enables rapid development and optimization of diverse conjugation processes across multiple bioconjugate modalities, including ADCs, RDCs, AOCs, APCs, and other emerging conjugates. Supported approaches include cysteine- and lysine-based conjugation, enzymatic methods, engineered cysteine approaches, glyco-remodeling, and interchain cysteine re-bridging. The Conjugation Toolbox was shortlisted in the ＂Best ADC Platform Technology＂ category at the 2025 World ADC Awards.4. IMPACT Drug Product Development Platform — Delivers indication-, molecule-, and phase-accountable drug product development services. Supported dosage forms include high-concentration, lyophilized, liquid, and frozen-liquid presentations, with an emphasis on formulation and process solutions for complex and high-potency biologics.5. Payload-Linker CMC Development Platform — Offers multiple payload and linker options, including payloads (e.g., Auristatin, Maytansine, Camptothecin, Eribulin, PBD dimer, macrocyclic molecular glue, E3 ligase ligand, and others) and linkers (e.g., peptide linkers, PEG linkers, sugar linkers, and others). The platform brings extensive CMC development experience, supporting more than 70 IND and 13 NDA projects.6. Comprehensive Analytical Platform — Capable of efficient analytical method development and in-depth product characterization, covering critical quality attributes (CQAs) across every stage of the product lifecycle, and comprising the Physicochemical Platform, Mass Spectrometry Platform, and Bioassay Platform.AsymBio will continue to invest in R&D and technology development, with a focus on advanced technology platforms and data-enabled manufacturing processes. The company noted that technology underpins pharmaceutical innovation; by integrating advanced scientific approaches with large-scale manufacturing experience, AsymBio works to help address complex challenges in biopharmaceutical development, improve manufacturing efficiency and product quality, and support the reliable commercialization of innovative therapies for global clients.About AsymBioAsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale manufacturing. Building on deep ADC experience, AsymBio is expanding into NDCs, including RDCs, AOCs, PDCs, APCs, BsADCs, and dpADCs, while maintaining comprehensive service capabilities for antibody therapeutics (monoclonal, bispecific, and multispecific antibodies) and protein-based therapeutics (fusion proteins, recombinant proteins).For more information: visit www.asymbio.com or follow us on LinkedIn. Business inquiries: MKT@asymchem.com.cn

We are excited to spotlight Dr. Tiejun Li, Vice General Manager of AsymBio, who will be presenting at the 16th Annual World ADC London on Feb 24, 2026 at 3:00 PM (ExCeL London). In his talk “Accelerating the Development of Next-Generation Bioconjugate Drugs Through an Integrated Platform,” Dr. Li will share insights on:• Key challenges in bioconjugation CMC development for novel NDCs• Case studies highlighting fit-for-purpose strategies for complex bioconjugation process development• AsymChem/AsymBio’s integrated capabilities in NDC CDMO services As a technology-driven global CDMO, AsymBio is committed to empowering innovators with robust, scalable, and regulatory-ready solutions across biologics and bioconjugates. If you are attending WorldADC2026, don't miss this session at ExCeL London - we look forward to connecting with you there!

Thrilled to share our highlights from the 2026 XDC & Antibody Drug Innovation Summit!The 2026 XDC & Antibody Drug Innovation Summit concluded successfully from January 6 to 7 at the DoubleTree by Hilton Hangzhou East Lake.As a trusted biologics CDMO, we showcased our next-gen ADC conjugation core technologies and one-stop platform solutions. Dr. Peng Qiang, Director of ADC Conjugation Process Development, delivered a standout keynote titled 《Accelerating Conjugation Process Development for Next-Generation ADCs: Key Considerations and Platform Strategies》—diving into random/site-specific conjugation, process challenges, and scalable industrialization insights, backed by 10+ years of experience across 30+ global bioconjugate projects.Great connections with industry innovators, exploring ADC development trends and collaboration opportunities!MKT@asymchem.com.cnhttps://www.asymbio.com/

Thrilled to Join AET2025: Powering Biologics Innovation Together!What an inspiring week in San Diego! From AI-driven antibody discovery and next-gen bispecific/multispecific formats to novel ADC payload strategies and hands-on workshops focused on developability, every session highlighted the game-changing work shaping our industry. It was an honor to engage with leading academics, biotech innovators, and industry peers—diving deep into the challenges and opportunities that define antibody development today. Whether you're advancing a promising antibody program or seeking a trusted partner to navigate the complexities of development, we're here to support your journey. Email: MKT@asymchem.com.cn Website:https://www.asymbio.com/

What a rewarding experience connecting with global biotech peers, researchers, and industry leaders at the 16th Annual World ADC San Diego 2025! The dynamic discussions around ADC innovation—from targeted conjugate technologies to commercial production challenges—reaffirmed our commitment to empowering cutting-edge therapies.AsymBio provides comprehensive, end-to-end CDMO services tailored to your program needs—spanning R&D, process optimization, CMC, cGMP manufacturing.Whether you're advancing a first-in-class ADC or optimizing a biologics pipeline, AsymBio is here to turn your vision into clinical reality. Let's connect to explore how our trusted CDMO services can accelerate your journey:Email: MKT@asymchem.com.cnConnect to our experts：https://lnkd.in/gjw5yruHSee you at the next breakthrough—let's innovate together!

AsymBio team is heading to Antibody Engineering & Therapeutics in San Diego. Come and meet us at Booth #518! With industry leading CDMO solutions for antibodies, bioconjugates, etc., AsymBio is the partner of choice for your success.Connect with AsymBio at global leading antibody event for discovery, engineering and therapeutic development in neurodegeneration, metabolism, autoimmunity & much more!

A Major Milestone for AsymBio: Shanghai Fengxian Commercial Production Base Is Officially Operational!We are thrilled to announce the official launch of our Shanghai Fengxian Commercial Production Base - our third core commercial hub alongside Jinshan and Zhangjiang, marking a game-changing leap for our global biologics CDMO service network. Spanning 130,000+ square meters, this cutting-edge facility is built and verified for NDCs(including ADCs), antibodies/TCEs, and recombinant proteins.Key highlights for global partners: --Phase I-A (Antibody Capacity): Fully operational with 200L/500L/2000L single-use bioreactors and 20㎡ lyophilizers, ready to support IND and late-stage commercial projects.--Phase I-B (NDC Capacity): To be Launched in Jan 2026 with specialized conjugation reactors and multi-scale lyophilizers, delivering flexible, manufacturing solutions.--Compliance with NMPA, FDA, and EMA standards, ensuring seamless global market access for our partners.This is not just a new facility—it is our commitment to accelerating your path from innovation to patient impact. With scalable capacity and end-to-end CDMO capabilities, we're here to turn your groundbreaking biologics into life-changing therapies!

AsymBio is Thrilled to Join the 16th World ADC San Diego! Mark your calendars for Nov 3rd–6th, 2025. We will be at Booth #59 to showcase cutting-edge integrated solutions for your bioconjugates! Whether you’re tackling complex PD challenges or scaling up production, our experts are ready to collaborate and innovate with you. Don’t miss this chance to explore the future of ADC technology. Swing by our booth and let’s connect! Special Highlight: On Nov 4th, join Dr. Kai Gao, CTO of AsymBio, as he takes the stage in the Manufacturing Track. His presentation, “Development of Robust and Scalable Bioconjugation Processes for Next-We are excited to share knowledge, forge partnerships, and push the boundaries of what is possible in bioconjugates. See you in San Diego!

AsymBio is thrilled to join the 3rd ADC Process Development Summit in Boston—our first time at this industry-leading gathering focused on advancing antibody-drug conjugate (ADC) process innovation.Not only are we attending-we are proud to serve as a sponsor, too! This event is all about bringing together ADC and bioconjugate experts, and we can’t wait to connect with both new industry peers and longstanding partners who share our drive to elevate biotherapeutic development.Stop by to chat with our team and learn more about our end-to-end integrated solutions for bioconjugates (including ADCs)—from pre-clinical development and clinical advancement all the way to commercialization. Whether you’re tackling process challenges or exploring scalable pathways for your program, we’re here to share insights and support your goals.See you in Boston!